Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for NextCell Pharma AB's FCF Margin % or its related term are showing as below:
OSTO:NXTCL'
s FCF Margin % Range Over the Past 10 Years
Min: -2865.76 Med: -702.1 Max: -355
Current: -408.76
During the past 11 years, the highest FCF Margin % of NextCell Pharma AB was -355.00%. The lowest was -2865.76%. And the median was -702.10%.
OSTO:NXTCL's FCF Margin % is ranked worse than 69.16% of 950
companies
in the Biotechnology industry
Industry Median: -81.28
vs OSTO:NXTCL: -408.76
NextCell Pharma AB FCF Margin % Related Terms
NextCell Pharma AB FCF Margin % Historical Data
* Premium members only.
The historical data trend for NextCell Pharma AB's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:NXTCL vs VRTX, REGN, RVMD: FCF Margin % Comparison
For the Biotechnology subindustry, NextCell Pharma AB's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NextCell Pharma AB FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NextCell Pharma AB's FCF Margin % distribution charts can be found below:
* The bar in red indicates where NextCell Pharma AB's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NextCell Pharma AB (OSTO:NXTCL) has a FCF Margin % of -574.05% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on NextCell Pharma AB and its competitors. According to the industry distribution chart, NextCell Pharma AB ranks #657 out of 950 companies in the Biotechnology industry, placing it in the top 69.2%.
Is NextCell Pharma AB's FCF Margin % too high?
NextCell Pharma AB's current FCF Margin % is -574.05%. Based on the distribution chart, NextCell Pharma AB ranks #657 out of 950 companies in the Biotechnology industry, which is below the industry midpoint. Overall, NextCell Pharma AB has a GF Score™ of 42/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NextCell Pharma AB's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, NextCell Pharma AB ranks #657 out of 950 companies for FCF Margin %. This places NextCell Pharma AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on NextCell Pharma AB and its competitors. NextCell Pharma AB's current FCF Margin % is -574.05%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NextCell Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, NextCell Pharma AB (OSTO:NXTCL) is currently considered Modestly Overvalued. The stock's GF Value™ is kr0.90, compared to a current price of kr1.01 — trading 12.2% above its estimated fair value. The current FCF Margin % is -574.05%. NextCell Pharma AB's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For NextCell Pharma AB (OSTO:NXTCL), the current FCF Margin % is -574.05% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NextCell Pharma AB (OSTO:NXTCL) Overvalued in 2026?
Based on GuruFocus' analysis, NextCell Pharma AB stock appears to be overvalued.
The current stock price of kr1.01 is trading 12.2% above its estimated GF Value™ of kr0.90.
GuruFocus considers NextCell Pharma AB to be Modestly Overvalued.
Key valuation signals for OSTO:NXTCL:
FCF Margin %: -574.05%
GF Value™: kr0.90 vs. price of kr1.01 (12.2% above fair value)
No single metric tells the full story. See the OSTO:NXTCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NextCell Pharma AB is a healthcare services provider. The company is engaged in the research of stem cell and is developing the candidate drug ProTrans for the treatment of diabetes and immunosuppression in kidney transplants.
42GF Score
Get the complete analysis for OSTO:NXTCL
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:NXTCL has been successfully added to your 
